Drug Trial Radar · NCT01358877
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,804
Actual
Start
Nov 8, 2011
Primary completion
Dec 19, 2016
Study completion Nov 28, 2024
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Genentech, Inc.; Breast International Group
- First posted
- May 24, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).
Conditions
- Breast Cancer
Interventions
5-FluorouracilDrug
5-Fluorouracil will be administered as per the schedule specified in the respective arm.
CarboplatinDrug
Carboplatin will be administered as per the schedule specified in the respective arm.
CyclophosphamideDrug
Cyclophosphamide will be administered as per the schedule specified in the respective arm.
DocetaxelDrug
Docetaxel will be administered as per the schedule specified in the respective arm.
DoxorubicinDrug
Doxorubicin will be administered as per the schedule specified in the respective arm.
EpirubicinDrug
Epirubicin will be administered as per the schedule specified in the respective arm.
PaclitaxelDrug
Paclitaxel will be administered as per the schedule specified in the respective arm.
PertuzumabDrug
Pertuzumab will be administered as per the schedule specified in the respective arm.
PlaceboDrug
Placebo will be administered as per the schedule specified in the respective arm.
TrastuzumabDrug
Trastuzumab will be administered as per the schedule specified in the respective arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory FindingsTime frame: Randomization to the first occurrence of IDFS event (excluding SPNBC) (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
- Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory FindingsTime frame: 3 years
Locations
546 sites in 42 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute ? Bisgrove
Scottsdale, Arizona
Providence Regional Medical Center
Everett, California
Marin Cancer Care Inc
Greenbrae, California
Kaiser Permanente - Hayward
Hayward, California
UCSD Moores Cancer Center
La Jolla, California
Cedars-Sinai Medical Center
Los Angeles, California
Kaiser Permanente - Oakland
Oakland, California
Kaiser Permanente - Roseville
Roseville, California
Sutter Cancer Center
Sacramento, California
Kaiser Permanente Sacramento Medical Center
Sacramento, California
Southern California Kaiser Permanente
San Diego, California
K. Permanente - San Fransisco
San Francisco, California
K. Permanente - San Jose
San Jose, California
K. Permanente - Santa Clara
Santa Clara, California
K. Permanente - S. San Fran
South San Francisco, California
Kaiser Permanente
Vallejo, California
K. Permanente - Walnut Creek
Walnut Creek, California
Rocky Mountain Cancer Center - Denver
Denver, Colorado
Lutheran Hematology &Oncology
Wheat Ridge, Colorado
Eastern Ct Hema/Onco Assoc
Norwich, Connecticut
Washington Cancer Institute at MedStar Washington Hospital Center.
Washington D.C., District of Columbia
Georgetown U
Washington D.C., District of Columbia
Florida Cancer Specialists
Fort Myers, Florida
Memorial Cancer Institute
Hollywood, Florida
Mayo Clinic-Jacksonville
Jacksonville, Florida
Cancer Specialists
Jacksonville, Florida
Ocala Oncology Center
Ocala, Florida
Memorial Breast Cancer Center
Pembroke Pines, Florida
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida
Florida Cancer Specialists
St. Petersburg, Florida
Florida Cancer Specialists, Research Department
West Palm Beach, Florida
Phoebe Putney Memorial Hospital
Albany, Georgia
Georgia Cancer Specialists
Atlanta, Georgia
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia
Kootenai Cancer Center
Post Falls, Idaho
Rush University Medical Center
Chicago, Illinois
Uni of Chicago
Chicago, Illinois
Ingalls Memorial Hospital
Harvey, Illinois
Loyola University Med Center
Maywood, Illinois
Edward Cancer Center Naperville
Naperville, Illinois
Showing 40 of 546 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.